Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWeill Medical College of Cornell University
About this trial
In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.
Eligibility criteria
Qualifiers
8 years of age or older.
Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English.
Access to a telephone with texting capacity.
Has not had prior genetic testing for hereditary cancer syndromes.
Disqualifiers
Under 18 years of age
Has had previous genetic testing for hereditary cancer syndromes
Does not read/speak in English
Does not have access to a phone with texting capabilities
Trial design
Treatments tested in this trial
- Chatbot
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov